AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca’s latest clinical study, officially titled ‘A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors,’ aims to evaluate the safety and effectiveness of AZD5335, an antibody-drug conjugate, in treating advanced tumors. This study is significant as it explores potential new treatments for ovarian cancer, lung adenocarcinoma, and endometrial cancer.
The study tests AZD5335 both as a standalone treatment and in combination with other anti-cancer agents, including Saruparib, Bevacizumab, Carboplatin, and AZD9574. These interventions are designed to assess the drug’s impact on various solid tumors, potentially offering new therapeutic options for patients.
This interventional study is randomized and follows a sequential intervention model, with no masking involved. Its primary purpose is treatment, focusing on the safety and tolerability of AZD5335 in different combinations.
The study began on February 21, 2023, with an estimated primary completion date in 2025. The last update was submitted on August 27, 2025, indicating ongoing progress and adjustments as necessary.
For investors, this study could influence AstraZeneca’s stock performance, especially if the results show positive outcomes. Success in this trial could enhance AstraZeneca’s position in the oncology market, potentially affecting competitor dynamics and investor sentiment positively.
The study is currently recruiting, with further details available on the ClinicalTrials portal.